Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Climb Bio, Inc. (Nasdaq: CLYM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Climb Bio is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for immune-mediated and B-cell mediated diseases, and its filings offer structured insight into how it reports material events, governance changes, and financial updates.
Recent Form 8-K filings describe key developments such as quarterly financial results, publication of clinical data for budoprutug in primary membranous nephropathy, and new preclinical data for CLYM116 in IgA nephropathy. Other 8-Ks detail the appointment of senior executives, including the Chief Financial Officer, and related equity awards granted under the company’s 2025 Inducement Plan, as well as amendments to increase the share reserve under that plan. These documents also confirm that Climb Bio’s common stock trades on The Nasdaq Global Market under the symbol CLYM.
Through Stock Titan, users can review Climb Bio’s SEC filings alongside AI-powered summaries that highlight the main points of each document. This includes explanations of how the company characterizes the therapeutic potential and clinical development of budoprutug and CLYM116 in its disclosures, and how it describes risks and forward-looking statements associated with its programs. The filings page is also a resource for tracking regulatory communications around investor events, data releases, and other reportable events.
By using this page, investors and researchers can quickly locate Climb Bio’s 8-Ks and other SEC reports and rely on AI-generated overviews to understand the significance of each filing without reading every line of the underlying documents.
Climb Bio director and 10% owner entities affiliated with RA Capital reported a major restructuring of their holdings and additional open-market share purchases. On December 11, 2025, RA Capital Healthcare Fund, L.P. exchanged 20,440,000 shares of Climb Bio common stock for a pre-funded warrant exercisable for up to 20,440,000 shares at an exercise price of $0.0001 per share, for no additional consideration.
The filing also reports open-market purchases of Climb Bio common stock: 213,099 shares on December 11, 2025 at a weighted average price of $2.18 per share and 101,462 shares on December 12, 2025 at a weighted average price of $2.86. The warrant has no expiration date, is exercisable immediately, and includes a 33.0% beneficial ownership cap, limiting how many shares can be exercised based on total outstanding stock. Climb Bio shares are held across multiple RA Capital funds and a separately managed account, with beneficial ownership relationships detailed among the affiliated entities.
Climb Bio (CLYM) reported third-quarter results marked by higher R&D investment and a solid liquidity position. Q3 net loss was $12.9 million, driven by research and development of $9.1 million and general and administrative of $5.8 million. For the nine months, net loss was $42.3 million.
Cash, cash equivalents and marketable securities were $175.8 million as of September 30, 2025, with stockholders’ equity of $177.0 million. Operating cash use was $38.7 million year to date. The company established an at‑the‑market program for up to $22.4 million and did not sell shares during the quarter. Shares outstanding were 68,184,435 as of October 31, 2025.
Pipeline progress included FDA clearance for a Phase 2 pMN study of budoprutug and an open‑label Phase 1b/2a study in ITP, with sites being activated and patients being enrolled and dosed. Climb also recorded a $9.0 million upfront expense earlier in the year for the CLYM116 license and noted milestone frameworks with Acelyrin, CRH and ProBioGen tied to future development and sales events.
Climb Bio, Inc. furnished a current report to share that it issued a press release on November 6, 2025 announcing its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to the report and is incorporated by reference. The company notes that this information is being furnished under the securities laws rather than treated as filed for liability purposes.
Climb Bio (CLYM) filed an 8-K announcing new long-term follow-up data for budoprutug, an anti‑CD19 monoclonal antibody in development for B‑cell mediated diseases. An abstract reports results from a previously conducted Phase 1b trial (NCT04652570) in primary membranous nephropathy.
The data showed long-term control of proteinuria for up to three years after initial dosing in four patients who received up to four doses of budoprutug. Three patients required no further immunosuppressive treatment during follow-up. No treatment‑related adverse events grade 3 or higher were observed in the trial.
The company’s forward‑looking statements section references development plans for budoprutug and CLYM116 and outlines risks including clinical progress, regulatory approvals, competition, intellectual property, and capital needs.
Amendment No. 4 to a Schedule 13D updates holdings and recent sales by Access Industries affiliates in Climb Bio, Inc. The Reporting Persons collectively own 3,835,117 shares, equal to 5.66% of the 67,764,100 shares outstanding as of July 31, 2025. The filing notes the issuer changed its name from "Eliem Therapeutics, Inc." to "Climb Bio, Inc." and its Nasdaq symbol to CLYM, effective October 2, 2024. The amendment discloses open-market sales by AI ETI totaling 75,383 shares on September 25–29, 2025 at weighted average prices around $2.11 per share, and on October 3, 2025 sales of 1,101,900 shares including a 1,100,000-share block trade at $1.9501 per share. The filing states control relationships among AI ETI, Access Industries Holdings, Access Industries Management and Len Blavatnik and includes a joint filing agreement.
Susan Altschuller, Chief Financial Officer of Climb Bio, Inc. (CLYM), received a stock option grant on October 1, 2025. The option gives the right to buy 600,000 shares of common stock at an exercise price of $1.97 per share and is exercisable through September 30, 2035. The option vests 25% on the first anniversary of the grant and the remainder in 36 equal monthly installments through October 1, 2029, subject to continued service. The reported ownership following the grant is 600,000 shares, held directly.
Climb Bio, Inc. filed an 8-K reporting an employment-related material event involving Susan Altschuller. The filing references an Offer Letter dated September 30, 2025 between Climb Bio and Dr. Altschuller and includes an electronic cover page in Inline XBRL dated October 1, 2025. The document also cites the company’s S-1 filed August 2, 2021, which contains an indemnification provision that may require the company to indemnify Dr. Altschuller for certain expenses (including attorneys’ fees), judgments, penalties, fines and settlement amounts reasonably incurred arising from her service to the company. The filing notes there are no family relationships between Dr. Altschuller and the company’s directors or officers.
Climb Bio, Inc. reported new preclinical results for its monoclonal antibody CLYM116, which targets APRIL and is being developed for IgA nephropathy. In a completed nonhuman primate study, CLYM116 showed deeper IgA reduction and a longer half-life compared with sibeprenlimab, a first-generation anti-APRIL antibody, suggesting a potential for less frequent dosing. Additional in vivo mouse studies showed enhanced APRIL elimination and antibody recycling versus sibeprenlimab.
The company plans, subject to regulatory clearance, to start a Phase 1 trial of CLYM116 in healthy volunteers in Q4 2025, with initial biomarker and dosing-interval data expected around mid-year 2026. Climb Bio is hosting a virtual investor event on September 29, 2025 to discuss these data, supported by a press release and presentation.
Schedule 13G: Pontifax-related entities report collective beneficial ownership of 5,206,380 shares of Climb Bio common stock, representing 7.7% of the class. The holdings are held in two limited partnerships (Pontifax (Israel) VI L.P. and Pontifax (Cayman) VI L.P.) controlled through Pontifax VI G.P. L.P. and Pontifax Management 4 G.P. (2015) Ltd., with Tomer Kariv and Ran Nussbaum identified as managing members. Reported power is shared voting and dispositive power over the full position; no sole voting or sole dispositive power is claimed.
Schedule 13G: Pontifax-related entities report collective beneficial ownership of 5,206,380 shares of Climb Bio common stock, representing 7.7% of the class. The holdings are held in two limited partnerships (Pontifax (Israel) VI L.P. and Pontifax (Cayman) VI L.P.) controlled through Pontifax VI G.P. L.P. and Pontifax Management 4 G.P. (2015) Ltd., with Tomer Kariv and Ran Nussbaum identified as managing members. Reported power is shared voting and dispositive power over the full position; no sole voting or sole dispositive power is claimed.